NANETS Members Co-Author Promising NET Research Findings

NANETS members have published research findings in the December edition of Clinical Cancer Research. Phase 1 Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan was conducted by NANETS members Diane Reidy-Lagunes, MD, Nitya Raj, MD, and Lisa Bodei, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSKCC), with colleagues, Neeta Pandit-Taskar, MD, Joseph A. O'Donoghue, PhD, Simone Krebs, MD, Kevin D. Staton, MD, Serge K. Lyashchenko, MD, Jason S. Lewis, MD, Mithat Gönen, PhD, Christian Lohrmann, MD, and Wolfgang A. Weber, MD. 

Read the abstract here.